Avidity Biosciences (RNA) Projected to Post Quarterly Earnings on Friday

Key Points

• Avidity Biosciences is set to release its Q2 2025 earnings on August 8th, with analysts predicting an earnings loss of ($0.93) per share and revenue of $1.61 million.
• The company recently missed analysts' earnings expectations for Q1, reporting ($0.90) EPS and $1.60 million in revenue compared to the anticipated $2.63 million.
• Despite recent insider selling, several institutional investors have increased their stakes, with Goldman Sachs raising its position by 2.8% and Royal Bank of Canada increasing its stake by 38.2% in the first quarter.

Avidity Biosciences (NASDAQ:RNA - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Friday, August 8th. Analysts expect Avidity Biosciences to post earnings of ($0.93) per share and revenue of $1.61 million for the quarter.

Avidity Biosciences (NASDAQ:RNA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.02). The business had revenue of $1.60 million during the quarter, compared to analyst estimates of $2.63 million. Avidity Biosciences had a negative net margin of 4,136.00% and a negative return on equity of 26.96%. On average, analysts expect Avidity Biosciences to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Avidity Biosciences Stock Performance

Shares of NASDAQ:RNA traded down $0.79 during midday trading on Friday, hitting $35.92. The company's stock had a trading volume of 2,254,318 shares, compared to its average volume of 2,798,632. Avidity Biosciences has a fifty-two week low of $21.51 and a fifty-two week high of $56.00. The stock has a market capitalization of $4.33 billion, a price-to-earnings ratio of -11.97 and a beta of 0.95. The stock's 50 day simple moving average is $31.98 and its 200 day simple moving average is $30.76.

Insider Buying and Selling

In other news, insider W. Michael Flanagan sold 20,000 shares of Avidity Biosciences stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $32.88, for a total value of $657,600.00. Following the completion of the transaction, the insider owned 80,195 shares in the company, valued at approximately $2,636,811.60. The trade was a 19.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Kathleen P. Gallagher sold 5,875 shares of Avidity Biosciences stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $32.48, for a total transaction of $190,820.00. Following the completion of the transaction, the insider owned 50,554 shares of the company's stock, valued at $1,641,993.92. This trade represents a 10.41% decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,786 shares of company stock valued at $875,969 in the last quarter. 3.83% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Strs Ohio bought a new position in shares of Avidity Biosciences in the first quarter valued at approximately $180,000. NewEdge Advisors LLC raised its stake in shares of Avidity Biosciences by 22.7% in the first quarter. NewEdge Advisors LLC now owns 23,837 shares of the biotechnology company's stock valued at $704,000 after acquiring an additional 4,410 shares during the last quarter. Royal Bank of Canada raised its stake in shares of Avidity Biosciences by 38.2% in the first quarter. Royal Bank of Canada now owns 44,304 shares of the biotechnology company's stock valued at $1,308,000 after acquiring an additional 12,241 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Avidity Biosciences by 7.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 357,718 shares of the biotechnology company's stock worth $10,560,000 after purchasing an additional 25,329 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Avidity Biosciences by 2.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 784,704 shares of the biotechnology company's stock worth $23,164,000 after purchasing an additional 21,649 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on RNA. HC Wainwright decreased their target price on Avidity Biosciences from $72.00 to $68.00 and set a "buy" rating on the stock in a research report on Monday, May 12th. Citigroup lifted their target price on Avidity Biosciences from $70.00 to $75.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Bank of America lifted their target price on Avidity Biosciences from $48.00 to $54.00 and gave the stock a "buy" rating in a research report on Monday, June 9th. Barclays lifted their target price on Avidity Biosciences from $57.00 to $59.00 and gave the stock an "overweight" rating in a research report on Tuesday, June 10th. Finally, JPMorgan Chase & Co. lifted their target price on Avidity Biosciences from $57.00 to $59.00 and gave the stock an "overweight" rating in a research report on Tuesday, June 10th. Sixteen analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $66.35.

Avidity Biosciences Company Profile

Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.